Shaw and Ritchey. One strategy for making certain AYA patients are treated by oncologists who are most up-to-date on medical trials and cutting-advantage treatment programs is certainly for pediatric oncology divisions to establish AYA oncology programs in cooperation with adult oncology counterparts. In 2006, Children’s partnered with colleagues from the University of Pittsburgh Cancers Institute to determine an unparalleled AYA Oncology Program.Bassam Damaj, Chief and President Executive Officer of Apricus Bio. ‘We believe it may allow us to go forward towards eventual authorization of the medication. Medical trials on the drug began after 2005, when NexMed signed an agreement with Novartis, under which Novartis assumed responsibility to build up and commercialize the medication. The first scientific trials did not show clear-cut efficacy, and in 2008, NexMed declared that the total results were not strong enough to support filing for fresh drug acceptance with the U.S.